We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Excimer Laser Angioplasty Shown Effective

By HospiMedica staff writers
Posted on 15 May 2001
A study has demonstrated that excimer laser coronary angioplasty (ELCA) is safe and effective for treating patients with acute coronary syndromes. More...
The findings were published in the April 1, 2001, issue of the American Journal of Cardiology.

The study involved 59 patients, 33 with unstable angina and 26 with acute myocardial infarction (AMI). Procedural success rates were 100% and 97% for the heart attack and angina patients, respectively. Two-thirds of the angina patients were within the indications cleared by the U.S. Food and Drug Administration (FDA) and were effectively treated with the laser, followed by balloon angioplasty. The laser used, the CVX-300, is the product of Spectranetics Corp. (Colorado Springs, CO, USA).

The findings in the study support the application of excimer laser angioplasty in selected patients with complex lesions who present with acute coronary syndromes,” said On Topaz, M.D., of the Medical College of Virginia Hospitals (Richmond, USA) and the lead investigator of the study. "Furthermore, the findings suggest that ultraviolet laser therapy results in thrombus removal and a high procedural success rate with minimal complications.”




Related Links:
Spectranetics

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.